Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Completed
Phase 2

Conditions

Dyslipidemia

Treatments

Drug: BMS-770767
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01058083
MB117-004
2009-014306-33 (Registry Identifier)

Details and patient eligibility

About

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)

Enrollment

81 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria: * Hypercholesterolemia * Currently taking a stable daily dose of statin therapy * Serum triglyceride level \< 500mg/dl Exclusion Criteria * History of myocardial infarction, coronary angioplasty or bypass grafts, valvular disease or repair, unstable angina pectoris, transient ischemic attack, or cerebrovascular accidents within six months prior to entry into the study * Congestive heart failure * Diabetes mellitus * Active liver disease * Impaired renal function * Hepatitis C, B and HIV This list is not inclusive additional information is provided in the protocol

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

81 participants in 5 patient groups, including a placebo group

BMS-770767 (Treatment A)
Experimental group
Treatment:
Drug: BMS-770767
BMS-770767 (Treatment B)
Experimental group
Treatment:
Drug: BMS-770767
BMS-770767 (Treatment C)
Experimental group
Treatment:
Drug: BMS-770767
BMS-770767 (Treatment D)
Experimental group
Treatment:
Drug: BMS-770767
Placebo (Treatment E)
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

14

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems